2-{4-[3-(3,4-dimethylphenyl)-1,2,4-oxadiazol-5-yl]-1-oxo-1,2-dihydrophthalazin-2-yl}-N-(4-ethylphenyl)acetamide

Catalog No. :
ACWKIA825
CAS No. :
1708251-27-7
Molecular Formula :
C28H25N5O3
Molecular Weight :
479.54

IUPAC Name:2-(4-(3-(3,4-dimethylphenyl)-1,2,4-oxadiazol-5-yl)-1-oxophthalazin-2(1H)-yl)-N-(4-ethylphenyl)acetamide

2-{4-[3-(3,4-dimethylphenyl)-1,2,4-oxadiazol-5-yl]-1-oxo-1,2-dihydrophthalazin-2-yl}-N-(4-ethylphenyl)acetamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g95%$321.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-{4-[3-(3,4-dimethylphenyl)-1,2,4-oxadiazol-5-yl]-1-oxo-1,2-dihydrophthalazin-2-yl}-N-(4-ethylphenyl)acetamide
IUPAC Name2-(4-(3-(3,4-dimethylphenyl)-1,2,4-oxadiazol-5-yl)-1-oxophthalazin-2(1H)-yl)-N-(4-ethylphenyl)acetamide
MDL No.MFCD26130047
Molecular FormulaC28H25N5O3
Molecular Weight479.54
SMILESO=C(NC1=CC=C(CC)C=C1)CN(N=C(C2=NC(C3=CC=C(C)C(C)=C3)=NO2)C4=C5C=CC=C4)C5=O
InChI KeyJCGZRKSNGSGXOT-UHFFFAOYSA-N
Synonym2-{4-[3-(3,4-Dimethyl-phenyl)-[1,2,4]oxadiazol-5-yl]-1-oxo-1H-phthalazin-2-yl}-N-(4-ethyl-phenyl)-acetamide;2(1H)-Phthalazineacetamide, 4-[3-(3,4-dimethylphenyl)-1,2,4-oxadiazol-5-yl]-N-(4-ethylphenyl)-1-oxo-
CAS No.1708251-27-7

Synthetic Route by SureRoute

1. ACWKIA825 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACWKIA825 route product structure diagram
    ACWKIA8251708251-27-7
Inquiry

2. ACWKIA825 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACWKIA825 route product structure diagram
    ACWKIA8251708251-27-7
Inquiry

Comments (0)